Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin

Archives of Internal Medicine

Volumn 158, Issue 21, 1998, Pages 2325-2328

  Goldhaber, Samuel Z ^a   Morrison, Ruth B ^a   Diran, Linda L ^a   Creager, Mark A ^a   Lee Jr , Thomas H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG COST; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOTAL KNEE REPLACEMENT;

EID: 0032561659     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.21.2325     Document Type: Article

References (12)

1. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am. 1994;76:1174-1185.
2. Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. Arch Intern Med. 1996;156:851-856.
3. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost. 1997;77:32-38.
4. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991; 151:333-337.
5. Polak JF. Peripheral Vascular Sonography: A Practical Guide. Baltimore, Md: Williams & Wilkins; 1992:162-166.
6. Simons GR, Skibo LR, Polak JF, Creager MA, Klapec-Fay JM, Goldhaber SZ. Utility of ultrasonography in suspected symptomatic isolated calf deep venous thrombosis. Am J Med. 1995;99:43-47.
7. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
8. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
9. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
10. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
11. Flessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195-199.
12. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.